Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porcel, J
Right arrow Articles by Montalbán, X
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porcel, J
Right arrow Articles by Montalbán, X
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 6, 802-807 (2006)
DOI: 10.1177/1352458506070748
© 2006 SAGE Publications

Long-term emotional state of multiple sclerosis patients treated with interferon beta

J Porcel

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain, jporcel{at}vhebron.net

J Río

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

A Sánchez-Betancourt

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

M J Arévalo

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

M Tintoré

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

N Téllez

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

C Borràs

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

C Nos

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

X Montalbán

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Objective: To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNß) for at least four years.

Methods: Patients who had started IFNß therapy prior to 2000 with a baseline psychological assessment were identified and scheduled for long-term emotional assessment with the following questionnaires-the Hamilton Depression Rating Scale, the Beck Depression Inventory and the State-Trait Anxiety Inventory.

Results: A total of 262 patients started IFNß therapy in our MS clinic within the period 1995-1999. Baseline emotional assessment was available from 246 MS patients. Long-term assessment was conducted on 234 patients. After a mean follow-up of 65 months (43-98), 52 patients (22.3%) had withdrawn from IFNß therapy. The comparisons, obtained from baseline and follow-up scores, showed an improvement in the depressive and anxiety symptoms of patients who adhered to IFNß treatment. Logistic regression analysis indicated that an increase in physical disability and the presence of depressive symptoms at baseline were best predictors for long-term depressive symptoms.

Conclusions: The present results support the absence of emotional worsening in MS patients treated with IFNß for a long period of time. Increased disability and the presence of baseline depressive symptoms predicted the presence of depressive symptoms at follow-up.

Key Words: depressive symptoms • follow-up • interferon beta • multiple sclerosis

References

  • Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FDet al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines . Neurology 2002; 58: 169-178 .[Free Full Text]
  • Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management . Neurology 1999; 53: 1622-1627 .[Abstract/Free Full Text]
  • The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .[Abstract/Free Full Text]
  • The IFNb Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1227-1285 .
  • Lana-Peixoto MA, Teixeira AL Jr, Haase VG. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis . Arch Neuro-Psiquiatria 2002; 60: 721-724 .
  • Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif) . Can J Psychiatry 2002; 47: 686-686 .[ISI][Medline] [Order article via Infotrieve]
  • Goeb JL, Cailleau A, Laine P, Etcharry-Bouyx F, Maugin D, Duverger Pet al. Acute delirium, delusion and depression during interferon-beta-1a therapy for multiple sclerosis: a case report . Clin Neuropharmacol 2003; 26: 5-7 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis . Arch Neurol 1997; 54: 531-533 .[Abstract]
  • Mohr DC, Likosky W, Dwyer P, Van der Wende J, Boudwyn A, Goodkin DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis . Arch Neurol 1999; 56: 1263-1265 .[Abstract/Free Full Text]
  • European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Borra`s C, Río J, Porcel J, Barrios M, Tintoré M, Montalbán X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b . Neurology 1999; 52: 1636-1639 .[Abstract/Free Full Text]
  • Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial . Mult Scler 2001; 7: 243-248 .[Abstract/Free Full Text]
  • Patten SB, Metz LM; SPECTRIMS Study Group. Interferon beta-1a and depression in secondary progressive MS: data from the SPECTRIMS trial . Neurology 2002; 59: 744-746 .[Abstract/Free Full Text]
  • Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort . Mult Scler 2003; 9: 616-620 .[Abstract/Free Full Text]
  • Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression. A prospective investigation . J Neurol 2002; 249: 815-820 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret Met al. Multiple sclerosis and depression: influence of interferon beta therapy . Mult Scler 2003; 9: 284-288 .[Abstract/Free Full Text]
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .[Abstract/Free Full Text]
  • Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials . Brain 1991; 114: 1057-1067 .[Abstract/Free Full Text]
  • Hamilton M. Development of a rating scale for primary depressive illness . Br J Soc Clin Psychol 1967; 6: 278-296 .[Medline] [Order article via Infotrieve]
  • Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression . Arch Gen Psychiatry 1961; 4: 561-571 .[ISI][Medline] [Order article via Infotrieve]
  • Spielberger CB, Gorsuch RL, Luschene RE. Cuestionario de ansiedad estado-rasgo (Spanish adaptation from the manual for the State-Trait Anxiety Inventory). TEA Ediciones , 1982.
  • Fernández JL, Mielgo M. EAE. Escala de apreciación del estrés. TEA Ediciones, 2001.
  • Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample . Am J Psychiatry 2002; 159: 1862-1868 .[Abstract/Free Full Text]
  • Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope . Mult Scler 2001; 7: 411-416 .[Abstract/Free Full Text]
  • Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population . Gen Hosp Psychiatry 2003; 25: 277-283 .[CrossRef][ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S. Patten, J. Williams, and L. Metz
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 406 - 411.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porcel, J
Right arrow Articles by Montalbán, X
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porcel, J
Right arrow Articles by Montalbán, X
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?